Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EPS (Basic) (2016 - 2025)

Cytokinetics (CYTK) has disclosed EPS (Basic) for 16 consecutive years, with -$2.73 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) changed N/A to -$2.73 in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.76, a N/A change, with the full-year FY2025 number at -$6.54, down 24.33% from a year prior.
  • EPS (Basic) was -$2.73 for Q4 2025 at Cytokinetics, down from -$2.55 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.23 in Q2 2022 to a low of -$2.73 in Q4 2025.
  • A 5-year average of -$1.28 and a median of -$1.34 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): plummeted 1800.0% in 2021, then skyrocketed 73.26% in 2022.
  • Cytokinetics' EPS (Basic) stood at -$0.32 in 2021, then tumbled by 378.13% to -$1.53 in 2022, then grew by 9.8% to -$1.38 in 2023, then rose by 1.45% to -$1.36 in 2024, then tumbled by 100.74% to -$2.73 in 2025.
  • Per Business Quant, the three most recent readings for CYTK's EPS (Basic) are -$2.73 (Q4 2025), -$2.55 (Q3 2025), and -$1.12 (Q2 2025).